WO2023020504A1 - 允许分段释放的睡眠调节类片剂及其制备方法 - Google Patents
允许分段释放的睡眠调节类片剂及其制备方法 Download PDFInfo
- Publication number
- WO2023020504A1 WO2023020504A1 PCT/CN2022/112853 CN2022112853W WO2023020504A1 WO 2023020504 A1 WO2023020504 A1 WO 2023020504A1 CN 2022112853 W CN2022112853 W CN 2022112853W WO 2023020504 A1 WO2023020504 A1 WO 2023020504A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- release
- drug
- tablet
- delayed
- shell
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000003826 tablet Substances 0.000 claims abstract description 146
- 239000003814 drug Substances 0.000 claims abstract description 129
- 229940079593 drug Drugs 0.000 claims abstract description 125
- 239000007950 delayed release tablet Substances 0.000 claims abstract description 73
- 239000002702 enteric coating Substances 0.000 claims abstract description 50
- 238000009505 enteric coating Methods 0.000 claims abstract description 50
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 49
- 239000011248 coating agent Substances 0.000 claims abstract description 30
- 238000000576 coating method Methods 0.000 claims abstract description 30
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 claims abstract description 20
- 229960001150 ramelteon Drugs 0.000 claims abstract description 20
- 239000000463 material Substances 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 40
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- 238000007906 compression Methods 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 20
- 230000006835 compression Effects 0.000 claims description 18
- 239000012907 medicinal substance Substances 0.000 claims description 18
- 238000004090 dissolution Methods 0.000 claims description 17
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 14
- 230000004584 weight gain Effects 0.000 claims description 14
- 235000019786 weight gain Nutrition 0.000 claims description 14
- 230000003111 delayed effect Effects 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 12
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 238000005550 wet granulation Methods 0.000 claims description 7
- 239000004925 Acrylic resin Substances 0.000 claims description 6
- 229920000178 Acrylic resin Polymers 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 6
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 5
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 5
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 229940032147 starch Drugs 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 3
- 125000005591 trimellitate group Chemical group 0.000 claims description 3
- MCUFTLAXJMCWPZ-UHFFFAOYSA-N 3-butyl-2-methylphenol Chemical compound CCCCC1=CC=CC(O)=C1C MCUFTLAXJMCWPZ-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 229920001531 copovidone Polymers 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940001607 sodium bisulfite Drugs 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 229940117958 vinyl acetate Drugs 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000008199 coating composition Substances 0.000 claims 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 abstract description 15
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 238000007922 dissolution test Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008188 pellet Substances 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 239000013022 formulation composition Substances 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000002798 spectrophotometry method Methods 0.000 description 4
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 3
- 241001391944 Commicarpus scandens Species 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229940121723 Melatonin receptor agonist Drugs 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
Abstract
Description
Claims (15)
- 一种允许睡眠调节类药物分段释放的片剂,其特征在于,其结构上每个片剂从内到外依次包含含药迟释片芯、不含药肠溶包衣、含药速释外壳、以及外壳包衣组成。
- 根据权利要求1所述的片剂,其特征在于,所述不含药肠溶包衣材料采用的成膜材料选自丙烯酸树脂Ⅰ号、Ⅱ号、Ⅲ号,邻苯二甲酸醋酸纤维素(CAP),羟丙基甲基纤维素邻苯二甲酸酯(HPMCP),聚醋酸乙烯邻苯二甲酸酯(PVAP),醋酸纤维素苯三酸酯(CAT),丙烯酸树脂EuS100、EuL100、甲基丙烯酸-甲基丙烯酸甲酯共聚物、甲基丙烯酸-丙烯酸乙酯共聚物中的一种或多种,优选采用的成膜材料为甲基丙烯酸和丙烯酸乙酯共聚物;
- 根据权利要求2所述的片剂,其特征在于,其中所述不含药肠溶包衣相对于含药迟释片芯增重≥4%,其在溶解条件为pH5以上可溶,使得迟释片芯在含药速释外壳释放完全后的0.5-4个小时开始释放并在0.1-6小时内释放完全。
- 根据权利要求3所述的片剂,其特征在于,其中所述不含药肠溶包衣相对于含药迟释片芯增重增重4%-12%、5%、增重6%、7%或8%,其在溶解条件为pH7以上可溶,使得迟释片芯在含药速释外壳释放完全后的0.5-4个小时开始释放并在0.5-4小时内释放完全。
- 根据权利要求1所述的片剂,其特征在于,优选在含药迟释片芯和不含药肠溶包衣之间还具有不含药胃溶包衣,所述不含药胃溶包衣增重2-5%;优选3%或4%。
- 根据权利要求1所述的片剂,其特征在于,所述含药速释外壳中与所述含药迟释片芯中的药效物质的含量比例为1-3:1。
- 根据权利要求1所述的片剂,其特征在于,所述含药迟释片芯为速释制剂,在所述含药迟释片芯中,各辅料的重量百分比含量分别为:填充剂60-90%;崩解剂2-10%,优选4-8%;粘合剂2-6%,优选2.5-5%;抗氧化剂0.01-1%,优选0.05-1%;润滑剂/助流剂0.5-3%,优选0.5-1.5%;其中填充剂、抗氧化剂为内加辅料,润滑剂/助流剂为外加辅料,崩解剂可以为内加辅料或者外加辅料;
- 根据权利要求1所述的片剂,其特征在于,所述含药迟释片芯为缓释制剂,在所述含药迟释片芯中,各辅料的重量百分比含量分别为:填充剂60-90%;粘合剂2-6%,优选2.5-5%;缓释材料4-25%,优选5-20%;抗氧化剂0.01-1%,优选0.05-1%;润滑剂/助流剂0.5-3%,优选0.5-1.5%;其中填充剂、粘合剂、抗氧化剂为内加辅料,润滑剂/助流剂为外加辅料。
- 根据权利要求1-8任一所述所述的片剂,其特征在于,所述含药速释外壳与所述含药迟释片芯的材料重量比为大于等于4,优选在4~12之间,或为350:60。
- 根据权利要求7或8所述的片剂,其特征在于,填充剂选自微晶纤维素、乳糖、预胶化淀粉、淀粉、磷酸氢钙、甘露醇、糊精中的一种或几种;粘合剂选自聚维酮、共聚维酮、羟丙基纤维素、羟丙甲纤维素等中的一种或几种;崩解剂选自淀粉、预胶化淀粉、低取代羟丙基纤维素、羧甲基淀粉钠、交联聚维酮、交联羧甲基纤维素钠中的一种或几种;缓释材料选自羟丙基纤维素、羟丙基甲基纤维素、海藻酸盐、乙基纤维素、醋酸乙烯酯、黄原胶、瓜尔胶、交联聚维酮、山嵛酸甘油酯中的一种或几种;抗氧化剂选自维生素E、对羟茴醚、丁羟茴醚、二丁甲苯酚、亚硫酸氢钠、焦亚硫酸钠和维生素C中的一种或多种;润滑剂/助流剂选自硬脂酸镁、硬脂富马酸钠、胶态二氧化硅、十二烷基硫酸钠、滑石粉中的一种或几种。
- 根据权利要求1-10任一所述的片剂,其特征在于:采用以下步骤制备而得:(1)配置所述含药速释外壳的材料:按配方制备含药速释外壳总混颗粒;(2)制备含药迟释片芯:配制含药迟释片芯总混颗粒,采用压制方法制得片芯;对片芯依次进行胃溶包衣和肠溶包衣得到含药迟释片芯;(3)将含药速释外壳的材料的一部分填入中模作为第一层;将含药迟释片芯放置于第一层上作为第二层,然后进行预压;填入含药速释外壳的其余材料作为第三层,进行压制 成片。
- 根据权利要求11任一所述的片剂,其特征在于:所述进行预压的压力为0.02-1.5kN,进行压制成片所采用的主压力为15-35kN。
- 根据权利要求1-12任一所述的片剂,其特征在于:其特征在于,所述睡眠调节药物指雷美替胺。
- 权利要求1-12任一所述的片剂的制备方法,其特征在于,包含以下步骤:(1)配置所述含药速释外壳的材料:按配方制备含药速释外壳总混颗粒;(2)制备含药迟释片芯:配制含药迟释片芯总混颗粒,采用压制方法制得片芯;对片芯依次进行胃溶包衣和肠溶包衣得到含药迟释片芯;(3)将含药速释外壳的材料的一部分填入中模作为第一层;将含药迟释片芯放置于第一层上作为第二层,然后进行预压;填入含药速释外壳的其余材料作为第三层,进行压制成片;优选地,所述的制备方法,其特征在于:所述进行预压的压力为0.02-1.5kN,进行压制成片所采用的主压力为15-35kN。
- 根据权利要求13所述的制备方法,其特征在于,所述制备含药迟释片芯总混颗粒及含药速释外壳总混颗粒采用以下任一方法:方法一:按处方量分别称取药效物质和过筛后的各种内加辅料,将药效物质及抗氧化剂加入一定量的溶剂中,制成溶液或混悬液喷入到其余内加辅料中完成湿法制粒,干燥后加入外加辅料,混合均匀,得相应总混颗粒;方法二:按处方量分别称取药效物质和过筛后的各种内加辅料;将药效物质加入一定量的溶剂中,制成溶液或混悬液喷入到内加辅料中完成湿法制粒,干燥后加入外加辅料,混合均匀,得相应总混颗粒;方法三:按处方量分别称取药效物质和过筛后的各种内加辅料,将抗氧化剂或粘合剂加入一定量的溶剂中,制成溶液或混悬液喷入到药效物质与其余内加辅料的混合材料中完成湿法制粒,干燥后加入外加辅料,混合均匀,得相应总混颗粒;方法四:按处方量分别称取药效物质和过筛后的各种辅料,按照等量递加方法将药效物质和辅料混合均匀,得相应总混颗粒。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22857815.9A EP4299056A1 (en) | 2021-08-18 | 2022-08-16 | Sleep regulation tablet allowing release by stage and preparation method therefor |
US18/288,382 US20240139110A1 (en) | 2021-08-18 | 2022-08-16 | Sleep-regulating tablet allowing release by stages and preparation method thereof |
JP2023559133A JP2024511202A (ja) | 2021-08-18 | 2022-08-16 | 段階的放出可能な睡眠調節錠剤及びその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110950477.6 | 2021-08-18 | ||
CN202110950477.6A CN115707455A (zh) | 2021-08-18 | 2021-08-18 | 允许睡眠调节类药物分段释放的片剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023020504A1 true WO2023020504A1 (zh) | 2023-02-23 |
Family
ID=85212581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/112853 WO2023020504A1 (zh) | 2021-08-18 | 2022-08-16 | 允许分段释放的睡眠调节类片剂及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240139110A1 (zh) |
EP (1) | EP4299056A1 (zh) |
JP (1) | JP2024511202A (zh) |
CN (1) | CN115707455A (zh) |
WO (1) | WO2023020504A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1488346A (zh) * | 2002-10-09 | 2004-04-14 | 重庆太极医药研究院 | 褪黑素双层控释片及制备工艺 |
WO2010075080A1 (en) * | 2008-12-15 | 2010-07-01 | Somnus Therapeutics, Inc. | A method of treating insomnia |
CN102316857A (zh) * | 2008-12-16 | 2012-01-11 | 莱博法姆公司 | 防止误用的控释配方 |
CN103550775A (zh) * | 2013-10-18 | 2014-02-05 | 广州共禾医药科技有限公司 | 一种抗失眠组合物及其应用及利用该组合物制备的多相脉冲顿释制剂及其制备方法 |
CN110290781A (zh) * | 2017-01-26 | 2019-09-27 | 南京三迭纪医药科技有限公司 | 胃肠特定部位控制释放的剂型 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0821732A2 (pt) * | 2007-12-17 | 2015-06-16 | Labopharm Inc | Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada |
CN102319218B (zh) * | 2011-09-22 | 2014-10-01 | 贝沃特医药技术(上海)有限公司 | 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法 |
CN102552107B (zh) * | 2012-01-12 | 2014-02-26 | 刘光权 | 含唑吡坦或其盐的双相释放制剂及其制备方法 |
CN110368371A (zh) * | 2014-04-08 | 2019-10-25 | 越洋医药开发(广州)有限公司 | 一种新型控释片 |
CN112472679A (zh) * | 2020-12-02 | 2021-03-12 | 上海汉维生物医药科技有限公司 | 双释放片及其制备方法 |
-
2021
- 2021-08-18 CN CN202110950477.6A patent/CN115707455A/zh active Pending
-
2022
- 2022-08-16 JP JP2023559133A patent/JP2024511202A/ja active Pending
- 2022-08-16 WO PCT/CN2022/112853 patent/WO2023020504A1/zh active Application Filing
- 2022-08-16 EP EP22857815.9A patent/EP4299056A1/en active Pending
- 2022-08-16 US US18/288,382 patent/US20240139110A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1488346A (zh) * | 2002-10-09 | 2004-04-14 | 重庆太极医药研究院 | 褪黑素双层控释片及制备工艺 |
WO2010075080A1 (en) * | 2008-12-15 | 2010-07-01 | Somnus Therapeutics, Inc. | A method of treating insomnia |
CN102316857A (zh) * | 2008-12-16 | 2012-01-11 | 莱博法姆公司 | 防止误用的控释配方 |
CN103550775A (zh) * | 2013-10-18 | 2014-02-05 | 广州共禾医药科技有限公司 | 一种抗失眠组合物及其应用及利用该组合物制备的多相脉冲顿释制剂及其制备方法 |
CN110290781A (zh) * | 2017-01-26 | 2019-09-27 | 南京三迭纪医药科技有限公司 | 胃肠特定部位控制释放的剂型 |
Also Published As
Publication number | Publication date |
---|---|
US20240139110A1 (en) | 2024-05-02 |
CN115707455A (zh) | 2023-02-21 |
EP4299056A1 (en) | 2024-01-03 |
JP2024511202A (ja) | 2024-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002330211B2 (en) | Timed, sustained release multi-particulate dosage forms of propranolol | |
JP2016531912A (ja) | 低1日用量で投与するためのフマル酸ジメチルを含む医薬組成物 | |
JP2012224642A (ja) | 安定長期放出経口投薬組成物 | |
AU2002330211A1 (en) | Timed, sustained release multi-particulate dosage forms of propranolol | |
EP1238662B1 (en) | Method for manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules | |
MX2008014455A (es) | Sistema de suministro de farmaco de dosis controlada. | |
US8697755B2 (en) | Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia | |
WO2021129735A1 (zh) | 一种固体制剂及其制备方法和用途 | |
CN112472679A (zh) | 双释放片及其制备方法 | |
US20150250742A1 (en) | Dosage Forms Containing Terbutaline Sulphate | |
WO2023020504A1 (zh) | 允许分段释放的睡眠调节类片剂及其制备方法 | |
WO2021197376A1 (zh) | 一种非布司他片 | |
CN102238944B (zh) | 用于制备生物粘附压制基质的方法 | |
WO2021197451A1 (zh) | 一种替格瑞洛的多元制剂 | |
CN107224585B (zh) | 一种包含非甾体抗炎药和质子泵抑制剂的组合物 | |
CN114432257B (zh) | 一种艾氟洛芬缓释片剂及其制备方法 | |
WO2024017411A1 (zh) | 一种双相控释制剂及其制备方法 | |
CN102600108A (zh) | 一种氟比洛芬缓释胶囊及其制备方法 | |
JP7330948B2 (ja) | トシル酸スプラタストを含む組成物 | |
WO2023208241A1 (zh) | 一种吡非尼酮持续性释放口服固体制剂 | |
Oliveira | Preparation and Characterization of a Time-Dependent Drug Delivery System by Tablet Press-Coating | |
Guðmundsson et al. | Development of zero-order release tablets using hydrophilic polymer matrices | |
CN115887399A (zh) | 一种司来帕格片剂及其制备方法 | |
CN111544404A (zh) | 一种艾地骨化醇控释片 | |
JP2021120397A (ja) | 低1日用量で投与するためのフマル酸ジメチルを含む医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22857815 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023559133 Country of ref document: JP Ref document number: 2022857815 Country of ref document: EP Ref document number: 22857815.9 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022857815 Country of ref document: EP Effective date: 20230926 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18288382 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |